KR-335 / Kernal Biologics - LARVOL DELTA

Kernal Biologics Announces Presentations at The International mRNA Health Conference (PRNewswire) - "Kernal Biologics, Inc...announced it will have three presentations at the International mRNA Health Conference being held in Boston and virtually from November 8th to 10th, 2022....'In a preclinical study of KR-335, our tumor-selective mRNA LNP, we demonstrate tumor regression, improved overall survival and complete responses across different murine tumor models as a monotherapy'....'In another presentation, we demonstrate how it's possible to develop mRNA 2.0 - novel mRNA therapies using engineered mRNA molecules to translate in specific tissues and cell types'....'In a third presentation,' Erkul continued, 'we describe a strategy to deliver mRNA to B cells specifically - reducing liver exposure while increasing drug delivery to extrahepatic tissues such as blood, spleen, and bone marrow. This may help to establish mRNA as a therapeutic modality in B cell-associated diseases'."

Preclinical • Oncology • Solid Tumor